TNFRSF8 and Hodgkins lymphoma: CD30 is already the target of brentuximab vedotin (BV), an antibody-drug conjugate that has been approved for relapsed/refractory Hodgkin’s Lymphoma and anaplastic large T-cell lymphomas, cutaneous T-cell lymphoma andCD30+ peripheral T-cell lymphomas.